Marco Investment Management LLC Boosts Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Marco Investment Management LLC raised its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 8.6% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 2,660 shares of the medical instruments supplier’s stock after acquiring an additional 210 shares during the quarter. Marco Investment Management LLC’s holdings in LeMaitre Vascular were worth $247,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. CANADA LIFE ASSURANCE Co raised its stake in LeMaitre Vascular by 44.7% in the first quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock valued at $1,472,000 after purchasing an additional 6,875 shares in the last quarter. Sequoia Financial Advisors LLC bought a new stake in shares of LeMaitre Vascular during the 2nd quarter worth $1,010,000. Janus Henderson Group PLC grew its position in LeMaitre Vascular by 554.7% in the first quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after acquiring an additional 47,218 shares in the last quarter. Harbor Capital Advisors Inc. increased its stake in LeMaitre Vascular by 240.2% in the second quarter. Harbor Capital Advisors Inc. now owns 11,296 shares of the medical instruments supplier’s stock valued at $929,000 after acquiring an additional 7,976 shares during the last quarter. Finally, Nicholas Investment Partners LP purchased a new stake in LeMaitre Vascular during the second quarter valued at about $3,900,000. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Up 2.0 %

NASDAQ:LMAT opened at $107.97 on Monday. The firm has a market capitalization of $2.43 billion, a P/E ratio of 59.00, a P/E/G ratio of 2.64 and a beta of 0.89. The company has a fifty day moving average of $93.85 and a 200 day moving average of $86.91. LeMaitre Vascular, Inc. has a 52 week low of $51.70 and a 52 week high of $108.09.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. During the same period in the prior year, the business posted $0.33 earnings per share. LeMaitre Vascular’s revenue for the quarter was up 15.6% on a year-over-year basis. As a group, analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Thursday, November 21st. This represents a $0.64 annualized dividend and a dividend yield of 0.59%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.97%.

Insider Activity at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 10.79% of the stock is owned by corporate insiders.

Analyst Ratings Changes

LMAT has been the subject of a number of research reports. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Thursday. Barrington Research increased their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price on the stock. Finally, JMP Securities lifted their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 20th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.